Day: September 1, 2020

TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that it has determined the fixed dividend rate on its Cumulative 5-Year Rate Reset Preferred Shares, Series G (the “Series G Shares”) (TSX: FFH.PR.G) for the five years commencing October 1, 2020 and ending September 30, 2025. The fixed quarterly dividends on the Series G Shares during that period, if and when declared, will be paid at an annual rate of 2.962% (C$0.185125 per share per quarter).Holders of Series G Shares have the right, at their option, exercisable not later than 5:00 p.m. (Toronto time) on September 15, 2020, to convert all or part of their Series G Shares, on a one-for-one basis, into Cumulative Floating Rate Preferred Shares, Series H (the “Series H Shares”) (TSX: FFH.PR.H), effective September...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES(In Canadian Dollars unless otherwise stated)TORONTO, Sept. 01, 2020 (GLOBE NEWSWIRE) — Trigon Metals Inc. (TSX-V: TM) (“Trigon” or the “Company”) announces that it has entered into an agreement with Cormark Securities Inc. (“Cormark”) as lead agent and including M Partners Inc. (collectively with Cormark the “Agents”), pursuant to which they have agreed to act as agents in connection with a fully marketed private placement offering of units of the Company (the “Units”) at a price of $0.35 per Unit for aggregate gross proceeds to the Company of a minimum of $5.0 million (the “Offering”).Each Unit will consist of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each full...

MELBOURNE, Australia, Sept. 01, 2020 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the “Company”), a leader in the development of genetic risk assessment tests, is pleased to announce that it received notification from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company has met the minimum stockholders equity requirement set forth in Listing Rule 5550(b)(1).Nasdaq has determined that the Company complies with Listing Rule 5550(b)(1), which requires a stockholders’ equity of $2.5 million. Since April 2020, Genetic Technologies has raised an aggregate of $16.37 million through offerings of its American Depositary Shares, and as a result, as of August 28, 2020, it has US GAAP stockholders’ equity in excess of $2.5 million.Accordingly, the Company’s American...

EMERYVILLE, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) — Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.Berkeley Lights’ management is scheduled for a fireside chat on Tuesday, September 15 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.berkeleylights.com.About Berkeley LightsBerkeley Lights is a leading Digital Cell Biology company focused on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products for our customers. The Berkeley Lights Platform captures deep phenotypic, functional, and genotypic information...

MINNEAPOLIS, Sept. 01, 2020 (GLOBE NEWSWIRE) — Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the closing of its previously announced underwritten public offering of 2,545,454 shares of common stock and the same number of warrants to purchase shares of common stock for a price to the public of $4.125 per share and warrant.  Gross proceeds to the company were approximately $10.5 million. Each warrant entitles the holder to purchase one share of common stock at an exercise price of $4.54 per share.Craig-Hallum Capital Group acted as sole book-running manager for the offering.A registration statement relating to the securities being sold in this offering was filed with the Securities and Exchange Commission...

Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisionsAntigen test accurately screens individuals with known exposure to infected SARS-CoV-2 patients, providing fast answers regarding their infection statusAffordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of care locations, or in resource-limited settingsPoint of care testing increases access to high quality diagnostics solutions for the detection of a current SARS-CoV-2 infection, regardless of laboratory testing infrastructure or patient mobilityBasel, 1 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will launch a SARS-CoV-2 Rapid Antigen Test, in late September, for markets accepting the...